Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.
Reinheit:
97.50%
CAS Nummer:
[947687-12-9]
Target-Kategorie:
IGF-1R
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten